A key limitation of the use of the CRISPR-Cas9 system for genome editing and other applications is the requirement that a protospacer adjacent motif (PAM) be present at the target site. For the most commonly used Cas9 from Streptococcus pyogenes (SpCas9), the required PAM sequence is NGG. No natural or engineered Cas9 variants that have been shown to function efficiently in mammalian cells offer a PAM less restrictive than NGG. Here we use phage-assisted continuous evolution to evolve an expanded PAM SpCas9 variant (xCas9) that can recognize a broad range of PAM sequences including NG, GAA and GAT. The PAM compatibility of xCas9 is the broadest reported, to our knowledge, among Cas9 proteins that are active in mammalian cells, and supports applications in human cells including targeted transcriptional activation, nuclease-mediated gene disruption, and cytidine and adenine base editing. Notably, despite its broadened PAM compatibility, xCas9 has much greater DNA specificity than SpCas9, with substantially lower genome-wide off-target activity at all NGG target sites tested, as well as minimal off-target activity when targeting genomic sites with non-NGG PAMs. These findings expand the DNA targeting scope of CRISPR systems and establish that there is no necessary tradeoff between Cas9 editing efficiency, PAM compatibility and DNA specificity.
The CRISPR-Cas9 system has facilitated widely used genome mani pulation capabilities including targeted gene disruption 1,2 , transcrip tional activation and repression 3 , epigenetic modification 3 , and direct conversion of a target base pair to a different base pair 4, 5 in a broad range of organisms and cell types 6 . CRISPR-Cas9 targets DNA in a manner that is programmed by an RNA (typically a singleguide RNA, or sgRNA 7 ) that contains a spacer sequence complementary to the target DNA site, the protospacer. In addition to a protospacer that complements the sgRNA, a Cas9 target site must also contain a PAM sequence to support recognition by Cas9. The NGG PAM requirement of canonical SpCas9, which occurs on average only once in every 16 randomly chosen genomic loci, greatly limits the target ing scope of Cas9 especially for applications that require precise Cas9 positioning, such as base editing, which requires a PAM approximately 13-17 nucleotides from the target base 4, 5 , and some forms of homology directed repair, which are most efficient when DNA cleavage occurs roughly 10-20 base pairs away from a desired alteration 8, 9 . These requirements limit the fraction of genomic DNA that can be targeted with CRISPR systems and highlight the need for more general genomeediting tools.
To address this limitation, researchers have harnessed natural CRISPR nucleases with different PAM requirements and engineered existing systems to accept variants of naturally recognized PAMs. Other natural CRISPR nucleases shown to function efficiently in mammalian cells include Staphylococcus aureus Cas9 (SaCas9) 10 , Acidaminococcus sp. Cpf1 11 , Lachnospiraceae bacterium Cpf1 11 , Campylobacter jejuni Cas9 12 , Streptococcus thermophilus Cas9 13 and Neisseria meningitidis Cas9 14 . None of these CRISPR nucleases, however, offers a PAM that occurs as frequently as that of SpCas9. Although CRISPR nucleases engineered to accept additional PAM sequences 15, 16 also expand the scope of genomic targets available for Cas9mediated manipulation, many target sequences remain inaccessible.
Here we used phageassisted continuous evolution (PACE) to rapi dly generate Cas9 variants that accept an expanded range of PAM sequences. During PACE, host Escherichia coli cells continuously dilute an evolving population of bacteriophages (selection phages). Because dilution occurs faster than cell division but slower than phage replica tion, only the selection phages, and not the host cells, can accumulate mutations 17 . Each selection phage carries a gene to be evolved instead of a phage gene (gene III) that is required for the production of infectious progeny phage. Selection phages that contain desired gene variants trig ger hostcell gene III expression from the accessory plasmid and the production of infectious selection phages that propagate the desired variants. Phages encoding inactive variants do not generate infectious progeny and are rapidly diluted out of the culture vessel ( Fig. 1a ). As phage replication can occur in as little as 10 min, PACE enables hun dreds of generations of directed evolution to occur per week without researcher intervention [17] [18] [19] [20] [21] [22] .
Evolution of Cas9 towards expanded PAM compatibility
To link Cas9 DNA recognition to phage propagation during PACE, we developed a bacterial onehybrid selection 20, 23, 24 in which the selec tion phage encodes a catalytically dead SpCas9 (dCas9) fused to the ω subunit of bacterial RNA polymerase. When this fusion binds an sgRNA encoded by the accessory plasmid and a PAM and protospacer upstream of gene III in the accessory plasmid, recruitment RNA poly merase causes gene III expression and phage propagation ( Fig. 1b) . We envisioned installing a library of all 64 possible NNN PAM sequences at the target protospacer in the accessory plasmid, so that selection phages encoding Cas9 variants with broader PAM compatibility would replicate in a larger fraction of host cells and thus experience a fitness advantage.
We optimized the relationship between Cas9 DNA binding and gene expression (Extended Data Fig. 1a-c) . These studies revealed that a fusion of the orientation N-ω-dCas9-C, together with a simple Ala-Ala fusion linker and the placement of the protospacer on the reverse complement strand 45 base pairs upstream of the −35 box results in the strongest guide RNAdependent gene expression activation (13fold) (Extended Data Fig. 1a-c) . Together, these results establish a linkage between Cas9 DNAbinding activity and gene expression in a selection system suitable for PACE.
Using this selection, we first allowed a selection phage encoding the ω-dCas9 fusion to selfoptimize on host cells containing an acces sory plasmid with a canonical NGG PAM, resulting in enrichment of an I12N mutation in the ω subunit. Adding this single mutation to ω-dCas9 boosted activation from 13fold to over 100fold (Extended Data Fig. 1d ), representing earlystage optimization of ω-dCas9 during PACE before evolution for broadened PAM compatibility.
To evolve Cas9 variants with expanded PAM compatibility we gene rated three accessory plasmid libraries, each containing a different sgRNA ( Supplementary Table 4 ) and a corresponding protospacer upstream of an NNN PAM library, in which N is an equimolar mixture of all four DNA bases. This design imposes selection pressure to recog nize many different PAM sequences, as well as to maintain compatibility with different target DNA sequences. All three accessory plasmid libraries were introduced into host E. coli cells harbouring the mutagen esis plasmid MP6 17 . The resulting host cells were incubated overnight with selection phages containing ω(I12N)-dCas9. This phageassisted noncontinuous evolution system 19, 21 preferentially replicates Cas9 vari ants that bind a greater variety of PAM sequences, similar to PACE, but with lower stringency since there is no outflow of the phages.
After 24 days of serial overnight propagation and 1:1,000 dilution, we isolated five Cas9 clones for sequencing and characterization (xCas91.0-xCas91.4). Notable recurring mutations include E480K, E543D and E1219V ( Fig. 1e and Supplementary Table 5 ). E1219 is close in the SpCas9 crystal structure to R1333 and R1335 ( Fig. 1c ), two residues that are known to have a critical role in PAM recog nition 25 . The mixture of phage from the final phageassisted non continuous evolution pool were further evolved for 72 h using PACE on host cells containing the same accessory plasmid libraries harbour ing NNN PAM sequences. Among the individual Cas9 clones emerg ing from PACE (xCas92.0-xCas92.6), E480K, E543D and E1219V were present in all sequenced phages, along with additional mutations seen in multiple clones, including A262T, K294R, S409I and M694I ( Fig. 1e and Supplementary Table 5 ). Finally, the resulting phages were continuously evolved using PACE for an additional 72 h on host cells containing three protospacer-sgRNA pairs and HHH PAM libraries, in which H is A, C, or T, to favour Cas9 variants with activity on non NGG PAMs.
Fourteen resulting evolved Cas9 variants (xCas93.0-xCas93.13) containing consensus mutations ( Fig. 1e and Supplementary Table 5 ) emerged from two apparent evolution trajectories. Although all phages shared E480K, E543D and E1219V core mutations, xCas93.0-xCas9 3.5 also all contained K294R and Q1256K mutations and xCas93.6-xCas93.13 all contained A262T, S409I and M694I mutations, with some of the latter also containing R324L. The Cas9 crystal structure predicts that R324L, S409I and M694I lie near the DNA-sgRNA interface ( Fig. 1d ) and could have a role in mediating DNA sequence recognition and the switching of Cas9 from the open to the closed con formation upon target recognition 26, 27 . Because the entire Cas9 gene was subject to mutagenesis during PACE, the mechanism of xCas9 may differ from that of engineered Cas9 variants that primarily mutated DNAcontacting residues 15, 16, 28 .
We characterized evolved xCas9 variants in several contexts. We first restored the catalytic residues D10 and H840 to test whether xCas9 nucleases can cleave DNA even though they were evolved only for DNA binding. The xCas93.0-xCas93.13 clones were tested in a PAM depletion assay 15, 16 in which they were given the opportunity to cleave a library of plasmids containing a protospacer and all possible NNN PAM sequences in an antibioticresistance gene in bacterial cells. Plasmid cleavage results in the loss of spectinomycin resistance. This PAM depletion assay revealed that xCas93.0-xCas93.3 and xCas9 3.5-xCas93.9 cleave DNA site with NG, NNG, GAA, GAT and CAA PAMs (Extended Data Fig. 2 ). The clone with the highest PAM deple tion score, xCas93.7, depleted NG, NNG, GAA, GAT and CAA PAMs by at least 100fold compared to the starting library, and xCas93.6 showed the second highest average PAM depletion score.
xCas9 activators and nucleases in human cells
To test whether mutations evolved during PACE in bacteria are compa tible with xCas9 function in mammalian cells, we characterized xCas9 variants for their activity and PAM compatibility in human cells in four contexts: transcriptional activation, genomic DNA cutting, cyti dine base editing and adenine base editing. All guide RNAs used in this study were transcribed from a U6 promoter, and natively started with a G at the 5′ end to avoid possible losses in activity caused by a mismatched 5′ guide terminus 15, 16, 29, 30 . To test for transcriptional activation, catalytically dead versions of xCas9 were fused to the transcriptional activator VP64-p65-Rta (dxCas9-VPR) 31 . Plasmids encoding dxCas9-VPR, a green fluorescent protein (GFP) reporter downstream of a target protospacer and a corresponding sgRNA were cotransfected into human HEK293T cells 31 . Targetgene transcrip tional activation was measured by cellular GFP fluorescence after three days. Three different targetsite PAM sets were tested: a single reporter with an NGG PAM, a reporter library containing a NNN PAM library and a reporter library containing a NNNNN PAM library. In addition, two different protospacer sequences, reporter 1 and reporter 2, were tested with their corresponding sgRNAs. Most early stage xCas9 variants outperformed wildtype SpCas9 on sites with NGG PAMs, as well as with NNN and NNNNN PAM libraries (Extended Data Fig. 3a ). For reporters 1 and 2, respectively, xCas93.7 achieved 2.8 and 1.5fold higher mean fluorescence for the NGG PAM, 7.9 and 2.1fold higher mean fluorescence for the NNN PAM library, and 5.2 and 1.7fold higher mean fluorescence for the NNNNN PAM library when compared with SpCas9 (Extended Data Fig. 3b , c). The similar performance of xCas93.7 on NNN and NNNNN PAM libraries suggests that it did not evolve strong sequence preferences at nucleotides immediately downstream of the NNN PAM. The xCas93.6 variant showed similar results to those of xCas93.7 in this assay (Extended Data Fig. 3b , c).
To dissect activity on individual PAM sequences, we tested dxCas9-VPR transcriptional activators on individual target sites containing each of the 64 possible threenucleotide PAM sequences ( Fig. 2a and Extended Data Figs 4-6) in HEK293T cells. Consistent with the PAM library results, dxCas9(3.7)-VPR showed broad improvements in tran scriptional activity relative to dSpCas9-VPR across many individual nonNGG PAMs. Transcriptional activation by dxCas9(3.7)-VPR at sites containing NGT, NGA, NGC, NNG, GAA and GAT PAMs aver aged 56-91% of the average activity of dxCas9(3.7)-VPR on the four NGG PAM sites ( Fig. 2a and Extended Data Fig. 5 ). The performance of xCas93.6 transcriptional activators was similar to that of xCas9 3.7 (Extended Data Fig. 6 ). To test whether broadened transcriptional activation by xCas9 is limited to reporter plasmids that may be only partially chromatinized, we also tested the ability of dxCas9(3.7)-VPR to activate transcription of six endogenous genomic loci in human cells and observed 3.3fold average improved activation of the two NGG PAM sites and 39fold average improved activation among the three NGN PAM sites, but no improvement on the tested NNG site, relative to dSpCas9-VPR (Extended Data Fig. 5e ). Overall, these results estab lish that xCas9 is compatible with the dCas9-VPR architecture and can serve as a potent transcriptional activator in human cells at a substan tially expanded set of PAMs. On the basis of their strong performance in the PAM depletion assay and as transcriptional activators, we chose xCas93.7 and xCas93.6 for further characterization.
To test targeted genomic DNA cleavage in human cells, we expressed xCas93.7 and 3.6 nuclease in a HEK293T cell line with a genomi cally integrated GFP gene and measured the loss of GFP fluorescence reflecting DNA cleavage and indelmediated disruption of the tar get site. There are two NGG PAM sites and three NGT sites present in the GFP sequence, as well as individual NGC, NGA, GAT, NCG and NTG sites. All of these PAM sequences were tested with SpCas9, xCas93.7 and xCas93.6. For the NGG PAM sites, xCas93.7 modestly out performed SpCas9, resulting in 46 ± 2.0% compared to 33 ± 3.4% GFP disruption for SpCas9 (mean ± s.d. of three independent repli cates, Fig. 2b ). For all tested nonNGG PAM sites, xCas93.7 showed substantially higher (1.6 to 5.1fold) average apparent cleavage activity than SpCas9 (Fig. 2b) . At all tested sites, xCas93.6 showed GFP disruption percentages that were similar to or slightly lower than those of xCas93.7 (Extended Data Fig. 7a ). Neither xCas93.7 nor xCas93.6 increased GFP loss relative to SpCas9 for either NNG PAM site tested, suggesting that the transcriptional activation by dxCas9-VPR observed at some NNG PAM sites, and the strong NNG PAM signal in the bacterial PAM depletion assay, do not necessarily trans late to DNA cleavage at all NNG sites in mammalian cells. Targetsite dependence is also wellknown for SpCas9 32 .
To further characterize DNA cleavage by xCas9 variants in human cells, we targeted endogenous genomic sites in HEK293T cells and measured indel formation by highthroughput sequencing (HTS). Twenty endogenous sites were tested covering four NGG PAM sites, all twelve possible NGT, NGC and NGA PAMs, and GAT, GAA and CAA PAMs (Fig. 2c ). On the four NGG PAM sites tested, xCas93.7 showed comparable activity to SpCas9, averaging 41 ± 6.4% indels compared to 41 ± 6.0% for SpCas9 ( Fig. 2c ). All four NGT PAM sites showed much higher indel formation with xCas93.7 than with SpCas9, aver aging 38 ± 4.1% indels compared to 8.6 ± 1.5% for SpCas9, a 4.5fold increase. The four NGA PAM sites averaged 32 ± 2.4% indels for xCas93.7 and 20 ± 2.7% for SpCas9, a 1.6fold increase, consistent with previous reports that NGA can serve as a secondary PAM for SpCas9 33 . Although indel frequencies at the endogenous NGC PAM sites were more variable, ranging from 4.8 to 31%, xCas93.7 aver aged 13 ± 0.90% indels compared to 6.3 ± 0.77% for SpCas9, a 2.1fold increase. Among the three GAA and GAT sites tested, SpCas9 showed virtually no activity, averaging 1.4 ± 1.3% indel formation, whereas xCas93.7 averaged 7.2 ± 2.8% indel formation, a 5.2fold increase. For all sites tested the xCas93.6 variant showed indel frequencies that were similar to or slightly lower than those of xCas93.7 (Extended Data Fig. 7b ). Negative control experiments lacking sgRNA plasmids resulted in no indels above background (Extended Data Fig. 8 ). Taken together, these results indicate that xCas93.7 nuclease mediates tar getgene disruption at NGG PAM sites with efficiencies that are com parable to wildtype SpCas9, but cleaves NG, GAA and GAT PAM sites with substantially higher efficiencies than SpCas9. The greater PAMdependent and protospacerdependent variability of xCas9 nucleasemediated gene disruption relative to transcriptional activa tion ( Fig. 2 and Extended Data Figs 5-7) may reflect more extensive requirements for DNA cleavage than DNA binding 27, 29 , or differences in the chromatin state of plasmid ( Fig 
Base editing by xCas9 variants in human cells
Base editing is a newer genome editing approach that uses a catalyti cally impaired Cas9 fused to a natural or laboratoryevolved nucleobase deaminase enzyme and, in some cases, a DNA glycosylase inhibitor to directly convert a target C•G to T•A, or a target A•T to G•C, without introducing doublestranded DNA breaks or requiring homology directed repair 4, 5, 34 . The suitability of a target site for base editing is highly dependent on the presence of a suitably positioned PAM, which must exist within a narrow window downstream of the target base pair (typically 15 ± 2 nucleotides). The broad PAM compatibility of xCas9 variants thus has the potential to expand the DNA targeting scope of base editors (Fig. 3c) .
To evaluate C•G-to-T•A base-editing activity of xCas9 variants, we substituted SpCas9 with xCas93.7 and 3.6 in the thirdgeneration (BE3) base editor architecture 4 . We separately transfected plasmids encoding xCas9(3.7)-BE3, xCas9(3.6)-BE3 and SpCas9-BE3 into mammalian cells to compare editing efficiency on all 20 sites tested above for endogenous genomic DNA cleavage ( Fig. 3a) . At the four NGG PAM target sites tested, xCas9(3.7)-BE3 averaged 37 ± 10% C•G-to-T•A conversion, whereas SpCas9-BE3 averaged 28 ± 5.2% ( Fig. 3a) . At the NG, GAA and GAT PAM sites tested, xCas9(3.7)-BE3 resulted in substantially improved base editing, averaging 24 ± 5.4% editing at NGT PAM sites, an 9.5fold increase compared with that of SpCas9; 16 ± 3.5% editing at NGA sites, a 3.5fold increase compared Article reSeArcH 6 0 | N a T U r E | V O l 5 5 6 | 5 a p r i l 2 0 1 8 with SpCas9; 6.2 ± 0.34% editing at NGC sites, a 13fold increase over SpCas9; 10 ± 0.75% editing on the GAA PAM site, a more than 50fold increase over SpCas9; and 12 ± 1.5% editing on the GAT sites, a greater than 100fold increase compared with SpCas9 (Fig. 3a) . The base edit ing efficiencies of xCas9(3.6)-BE3 were comparable to, or slightly worse than, those of xCas9(3.7)-BE3 (Extended Data Fig. 7c ). We also tested cytosine base editing at an additional 15 endogenous genomic sites within the FANCF gene and observed similar large improvements for xCas9(3.7)-BE3 over SpCas9-BE3 (Extended Data Fig. 9a ). Overall, these results indicate that xCas9 variants are compatible with the BE3 architecture enabling cytidine base editing of target sites that cannot be accessed by SpCas9-BE3 or, with the exception of NGA PAM CGC S10 TGC S11 GGC S12
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CAA S20 sites 34 , by any other previously reported base editors. We also tested xCas93.7 in the BE4 architecture that was designed to reduce undesired byproducts 35 . In this system, fewer indels and higher product puri ties were observed, although editing efficiencies were slightly lower (Extended Data Fig. 9b-d ).
The recent development of an adenine base editor (ABE) enables programmable installation of A•T-to-G•C mutations 5 . No ABEs have been reported that can target nonNGG PAM sites, limiting its tar geting scope. We replaced SpCas9 in ABE 7.10 (ref. 5) with xCas93.7 and 3.6, and assayed the resulting xCas9-ABEs in HEK293T cells at the seven endogenous genomic sites tested above that contain an A in the targeting window of ABE (positions 4-8, counting the PAM as positions [21] [22] [23] . At all seven of these sites, xCas9(3.7)-ABE resulted in higher baseediting efficiencies than the original SpCas9-ABE (Fig. 3b ). Average baseediting efficiency at the NGG PAM site tested increased from 48 ± 2.1% to 69 ± 3.7%. At the GAT PAM site tested, xCas9(3.7)-ABE resulted in 16 ± 1.5% base editing, whereas SpCas9-ABE yielded no detectable editing (at most 0.1%), representing a more than 100fold increase. On the two NGC and three NGA sites tested, xCas9(3.7)-ABE averaged 21 ± 2.5% and 43 ± 1.5% base editing, respectively, whereas SpCas9-ABE averaged 7.0 ± 1.3% and 22 ± 1.2%, respectively. Base editing by xCas9(3.7)-ABE was comparable to or higher than that of xCas9(3.6)-ABE (Extended Data Fig. 7d ). Collectively, these results establish that xCas9-ABE mediates adenine base editing at sites that cannot currently be accessed.
Improved DNA specificity of xCas9 in human cells
Because PAM recognition is a crucial component of Cas9 DNA spec ificity 27 , the substantially broadened PAM compatibility of xCas9 proteins would be expected to increase their offtarget activity 29, 36 . Indeed, the engineered S. aureus KKHSaCas9, which accepts an NNNRRT PAM instead of the native NNGRRT SaCas9 PAM, exhib its similar or higher levels of offtarget editing than SaCas9 15 . Most of the xCas9 mutations are close to the PAM or to the DNA-sgRNA interface ( Fig. 1) , raising the possibility that these mutations might alter the degree to which mismatches between the spacer and proto spacer impede productive DNA binding or editing. Previous studies have demonstrated that some mutations near the Cas9-DNA interface can reduce offtarget activity, in some cases without affecting ontarget modification efficiency 26, 37, 38 .
To test the offtarget activity of xCas9 variants, we performed genomewide, unbiased identification of doublestrand breaks ena bled by sequencing (GUIDEseq), an offtarget analysis method 29 , of xCas93.7, xCas93.6 and SpCas9 in HEK293T and U2OS cells. Notably, for all five endogenous genomic NGG PAM sites tested in HEK293T cells and for both NGG PAM sites tested in U2OS cells, CGG S1 TGC S11 GGC S12
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CAA S20 GUIDEseq analysis revealed that xCas93.7 and 3.6 resulted in much lower offtarget activity than SpCas9, as reflected by both the number of detected offtarget sites as well as the total modifica tion frequency at each detected offtarget site ( Fig. 4 and Extended Data Fig. 10 ). For example, at the EMX1 target site in HEK293T cells, SpCas9 showed 5,649 ontarget reads and a total of 1,132 off target reads, whereas xCas9 3.7 showed 6,874 ontarget reads but no offtarget reads (Fig. 4b) . In U2OS cells, the offtarget to ontarget ratio for the same site was 0.65 for SpCas9 with 6,328 ontarget reads, and 0.015 for xCas93.7 with 22,539 ontarget reads, representing a 43fold reduction in offtarget modification (Extended Data Fig. 10c ). Likewise, for HEK sites 1, 2 and 3, xCas93.7 resulted in at least 100 fold lower offtarget to ontarget modification ratios (0.023, less than 0.001 and 0.028, respectively) than those of SpCas9 (0.28, 0.14 and 0.33, respectively) ( Fig. 4 and Extended Data Fig. 10 ). For the known highly promiscuous target sites HEK site 4 and VEGFA 29 , the offtarget to ontarget ratios were 9.4 and 2.0, respectively, for SpCas9, but only 1.0 and 0.48 for xCas93.7, a 4.2 to 9.4fold improvement (Extended Data Fig. 10 ). We observed these large improvements in DNA specificity for xCas93.7 and 3.6 even though xCas9 variants showed a much broader range of PAM sequences among detected offtarget sites ( Fig. 4 and Extended Data Fig. 10 ). The GUIDEseq results were verified by HTS of many individual ontarget and off target sites from the genomic DNA of treated cells (Extended Data Fig. 11 ).
We also evaluated the offtarget DNA specificity of both SpCas9 and xCas93.7 at two nonNGG PAM (GAA and CGT) sites in HEK293T cells. As expected, GUIDEseq did not yield any ontarget reads for SpCas9 at either of these nonNGG PAM sites, whereas xCas93.7 had 3,627 ontarget reads for the GAA PAM site and 3,055 ontarget reads for the CGT PAM site (Fig. 4e, f) . Notably, neither site exhibited any detected offtarget GUIDEseq reads for xCas93.7, although potential offtarget reads were detected for SpCas9 (Fig. 4e, f) . Collectively, these findings reveal that xCas93.7 and 3.6 offer greatly reduced offtarget activity compared with wildtype SpCas9, despite their broader PAM compatibility. These results also establish that there is no tradeoff between Cas9mediated editing efficiency, PAM compatibility and DNA specificity, a key finding as natural and engineered genome editing agents advance into widespread applications including human clinical trials.
These results, together with the success of multiple independent efforts to create highfidelity Cas9 variants 26, 37, 38 , suggest that the DNA promiscuity of wildtype Cas9, which probably evolved to impede viral evasion, can be overcome by protein engineering or evolution. That xCas9 exhibits much higher DNA specificity than SpCas9 even though it was not explicitly selected for this property suggests that the off target activity of wildtype SpCas9 may lie at a narrow fitness peak that is suitable for defending the much smaller bacterial genome but not optimal for genome editing in mammalian cells. These observa tions are therefore consistent with a model in which native SpCas9 is poised to become more specific, rather than less specific, upon suffi cient mutation. To our knowledge, the targeting scope of xCas9 is the broadest among Cas9 variants known to function efficiently in mammalian cells. Evolved xCas9 variants are also the first to offer improvements in tar geting scope, editing efficiency and DNA specificity in a single entity relative to wildtype SpCas9. Although the efficacy of xCas9 on non NGG PAMs varies based on application (transcriptional activation, DNA cleavage or base editing) and on target site, the ability to access some NG, GAA and GAT PAM sequences greatly expands the breadth of targets available for sitesensitive genome editing applications. Compared to SpCas9-BE3, xCas9(3.7)-BE3 increases the percentage of the 4,422 pathogenic singlenucleotide polymorphisms (SNPs) in the ClinVar database 39 that could, in principle, be targeted by C•G-to-T•A base editing from 26% to 73% (Fig. 3c) . Likewise, xCas9(3.7)-ABE increases the fraction of the 14,969 pathogenic SNPs in ClinVar that could be targeted by A•T-to-G•C base editing from 28% to 71% (Fig. 3d ). We anticipate that xCas9 and additional CRISPR enzyme variants with broadened PAM compatibilities may also expand the scope of other forms of nucleic acid editing, CRISPRbased screens and epigenetic modification.
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No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. General methods and cloning. DNA sequences used in this work are listed in the Supplementary Information. PCR was performed using Q5 Hot Start High Fidelity DNA Polymerase (New England Biolabs) or Phusion U Green Multiplex PCR Master Mix (Thermo Fisher Scientific). PACE plasmids and phages were constructed by USER cloning or Gibson cloning (New England Biolabs). Cas9 genes and plasmid backbones for PACE were obtained from previously reported plasmids 19, 20 that are available from Addgene. Plasmids encoding dxCas9-VPR 31 , xCas9 nucleases, xCas9-BE3 4 , xCas9-BE4 35 and xCas9-ABE 5 were constructed by replacing SpCas9 using Gibson cloning. Plasmids for sgRNA expression were con structed using onepiece bluntend ligation of a PCR product containing a variable 20nucleotide sequence corresponding to the desired sgRNA targeted site. Primers and templates used in the synthesis of all sgRNA plasmids used in this work are listed in Supplementary Tables 8, 9 , 11, 12, 15 and 16. PCR was performed using Q5 Hot Start HighFidelity Polymerase (New England Biolabs) with phosphorylated primers and the plasmid pFYF1320 (sgRNA expression plasmid with a spacer for targeting enhanced GFP (eGFP)) as a template according to the manufacturer's instructions. PCR products were analysed by agarose gel electrophoresis, the band of the expected molecular weight was excised, and the DNA was extracted using a Zymoclean Gel DNA Recovery Kit (Zymo Research) and ligated using T4 DNA Ligase (New England Biolabs) according to the manufacturer's instructions. DNA vector amplification was carried out using Mach1 competent cells (Thermo Fisher Scientific). All mammalian ABE constructs, sgRNA plasmids and bacterial constructs were transformed and stored as glycerol stocks at −80 °C in Mach1 T1 R Competent Cells (Thermo Fisher Scientific), which carry a recA mutation. Molecular biology grade Hyclone water (GE Healthcare Life Sciences) was used in all assays and PCR reactions. All vectors used in evolution experiments and mammalian cell assays were purified using ZymoPURE Plasmid Midiprep (Zymo Research), which includes endotoxin removal. Antibiotics were purchased from Gold Biotechnology. Cell culture. HEK293T (ATCC CRL3216) and U2OS (ATCCHTB96) cells were maintained in DMEM plus GlutaMax (Thermo Fisher Scientific) supplemented with 10% (v/v) fetal bovine serum (FBS) at 37 °C with 5% CO 2 . Cell lines tested negative for mycoplasmid contamination. Transfections. HEK293T cells were seeded on 48well polydlysinecoated BioCoat plates (Corning) and transfected at approximately 85% confluency. For genomic DNA cutting or base editing, 750 ng of Cas9 or BE3 and 250 ng of sgRNA expression plasmids were transfected using 1.5 μl of Lipofectamine 2000 (Thermo Fisher Scientific) per well according to the manufacturer's protocol. For GFP acti vation, 200 ng of dCas9-VPR plasmid, 50 ng of sgRNA expression plasmid, 60 ng of GFP reporter plasmid and 30 ng of nearinfrared fluorescent protein (iRFP) expression plasmid were transfected using 1.5 μl Lipofectamine 2000 (Thermo Fisher Scientific) per well according to the manufacturer's protocol. Endogenous gene activation was performed similarly but with 200 ng of dCas9-VPR plasmid and 50 ng of sgRNA expression plasmid only. GFP transcriptional activation assay. Transfected HEK293T cells were trypsin ized and resuspended in DMEM plus GlutaMax (Thermo Fisher Scientific) sup plemented with 10% (v/v) FBS. The cells were kept on ice and flow cytometry was performed using a LSRFortessa from BD Biosciences. Events were gated for iRFPpositive cells to analyse transfected cells. The percentage of GFPpositive cells and the intensity of GFP fluorescence from each cell was collected.
RNA expression quantification for endogenous transcriptional activation assay.
RNA was extracted from HEK293T cells using the QuickRNA Plus Kit (Zymo Research). cDNA was synthesized using the iScript cDNA Synthesis Kit (BioRad) and quantitative PCR (qPCR) was performed on a BioRad CFX96 RealTime PCR Detection System using Q5 Polymerase (New England Biolabs) and SYBR Green (Lonza). Primers for qPCR are listed in Supplementary Table 10 . PAM depletion assay. Electrocompetent NEB 10beta cells (New England Biolabs) were electroporated with two plasmids. The first plasmid expresses Cas9 (induc ible with anhydrotetracycline, ATc), the sgRNA (inducible with arabinose) and a spectinomycinresistance gene. The second plasmid contains the target protospacer and a kanamycinresistance gene. After incubation with SOC outgrowth medium (New England Biolabs) for 1 h the bacteria were plated on agar plates containing both spectinomycin and kanamycin along with ATc and arabinose inducers. After incubating overnight, the bacterial cells on the agar plates were scraped and the plasmids extracted using the ZymoPURE Plasmid Midiprep Kit (Zymo Research). The resulting postselection DNA included all of the protospacer plasmids not cleaved by Cas9. The same region around the protospacer in the preselection library and the postselection DNA was then amplified separately using NEBNext HighFidelity PCR Polymerase (New England Biolabs) with the flanking HTS primer pairs that are listed in the Supplementary Table 7 . The Illumina barcoding PCR reaction was assembled with NEBNext HighFidelity PCR Polymerase. PCR products were purified by electrophoresis with a 2% agarose gel using a QIAquick Gel Extraction Kit, eluting with 15 μl of water. DNA concentration was quanti fied with the KAPA Library Quantification KitIllumina (KAPA Biosystems) and sequenced on an Illumina MiSeq instrument according to the manufacturer's protocols. High-throughput DNA sequencing of genomic DNA samples. Transfected cells were harvested after 3 days (BE3 and BE4) or 5 days (DNA cutting and ABE). Medium was removed and cells were washed with 1× PBS solution (Thermo Fisher Scientific). Genomic DNA was extracted by addition of 100 μl freshly prepared lysis buffer (10 mM TrisHCl, pH 7.0, 0.05% SDS, 25 μg ml −1 proteinase K (Thermo Fisher Scientific)) directly into each well of the tissue culture plate. The plate was incubated at 37 °C for 1 h. The genomic DNA mixture was transferred to a 96well PCR plate and incubated at 80 °C for 15 min to denature enzymes. Genomic regions of interest were amplified by PCR with flanking HTS primer pairs that are listed in Supplementary Table 13 . Each 25 μl PCR reaction was assembled with Phusion Hot Start II HighFidelity DNA Polymerase (Thermo Fisher Scientific) according to the manufacturer's instructions using 1.0 μM forward and reverse primer and 1 μl of genomic DNA extract. PCR reactions were carried out under the following conditions: 95 °C for 3 min, then 30 cycles of 98 °C for 30 s, 60 °C for 20 s and 72 °C for 1 min, followed by a final 72 °C extension for 5 min. PCR products were verified by comparison to DNA standards (1kb Plus DNA Ladder) on a 2% agarose gel with ethidium bromide. Each 25μl Illumina barcoding PCR reaction was assem bled with Phusion DNA polymerase according to the manufacturer's instructions using 0.5 μM unique forward and reverse Illumina barcoding primer pair and 1 μl of unpurified genomic amplification PCR reaction mixture. The barcoding reactions were carried out as follows: 98 °C for 2 min, then 8 cycles of 98 °C for 12 s, 61 °C for 25 s and 72 °C for 30 s, followed by a final 72 °C extension for 1.5 min. PCR products were purified by electrophoresis with a 2% agarose gel using a QIAquick Gel Extraction Kit, eluting with 15 μl of water. DNA concentration was deter mined with the KAPA Library Quantification KitIllumina (KAPA Biosystems) and sequenced on an Illumina MiSeq instrument according to the manufacturer's protocols. Analysis was carried out using previously published Matlab code 5 that is provided in Supplementary Notes 1 and 2 .
Analysis of human disease-associated mutations in ClinVar database.
Bioinformatic analysis of the ClinVar database was carried out in a manner similar to previously described analysis 34 . The code is provided in Supplementary Note 3. GUIDE-seq. HEK293T cells were transfected with 750 ng of the Cas9 plasmid, 250 ng of the sgRNA plasmid and 20 pmol of GUIDEseq dsODN. U2OS cells were transfected with 750 ng of the Cas9 plasmid, 250 ng of the sgRNA plasmid and 100 pmol of GUIDEseq dsODN. For both cell types, 20 μl of solution SE (Lonza) was used along with a Lonza Nucleofector 4D. Program CM137 was used for HEK293T cells and program DN100 was used for U2OS cells. Genomic DNA was extracted using the QuickDNA Miniprep Plus Kit (Zymo Research) following the manufacturer's protocol. The DNA was sheared to an average of 500 base pairs using a Covaris S220 focused ultrasonicator as previously described 29 . End repair, dAtailing, adaptor ligation, tagspecific PCR1 and tagspecific PCR2 were carried out using the primers and methods described previously 29 . DNA concentration was quantified with the KAPA Library Quantification KitIllumina (KAPA Biosystems) and sequenced on an Illumina MiSeq instrument according to the manufacturer's protocols. Analysis was carried out using previously published Python code 29 . Data availability. Highthroughput sequencing data have been deposited in the NCBI Sequence Read Archive database under accession code SRP130166. GUIDE seq sequencing files listed in Supplementary Table 17 . Plasmids encoding the xCas93.7 and 3.6 transcriptional activators, nucleases, BE3, BE4 and ABE have been deposited with Addgene. CGC S10 TGC S11 GGC S12
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Experimental design 1. Sample size
Describe how sample size was determined. Experiments were done in biological triplicate, n=3. In previous studies we determined this sample size to be sufficient to ensure reproducibility.
Data exclusions
Describe any data exclusions.
No data was excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful, and standard deviations were within expected ranges.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Different cell passages were used for each biological replicate.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Not applicable
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
